文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

利用CRISPR/Cas9与人类诱导多能干细胞判定意义未明基因变异致病性

Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
PubMed 文献 · Circulation · 2018-01-01

该研究从一名无心脏病临床史的无症状「健康」个体中获取携带MYL3基因变异(NM_000258.2:c.170C>A, NP_000249.1:p.Ala57Asp)的iPSCs,该变异被ClinVar数据库报告为「可能致病」。利用CRISPR/Cas9基因组编辑构建4种同源iPSC系并分化为心肌细胞,进行基因表达、肌节结构、细胞大小、收缩力、动作电位和钙处理等检测。结果显示杂合VUS MYL3(170C>A)-iPSC-CMs未表现出HCM表型,纯合VUS和移码突变iPSC-CMs也无症状,支持该变异为良性;而携带已知致病突变MYL3(170C>G)和MYBPC3(961G>A)的细胞系则显示可提供致病性评估。该平台有望作为HCM相关VUS及一般VUS的风险评估工具。

要点

  • CRISPR/Cas9编辑携带者iPSCs可分化为心肌细胞,用于VUS功能评估
  • 杂合VUS MYL3(170C>A)未显示HCM表型,支持良性判定
  • 该平台能同时提供致病性和良性评估,有助精准医学

核心结论

  • CRISPR/Cas9基因组编辑携带者特异性iPSCs可在培养皿中阐明HCM的良性和致病性功能表型,该平台是评估HCM相关VUS及一般VUS的 promising 风险工具。

研究设计与样本

  • 研究招募一名无心脏病临床史的无症状「健康」个体,携带HCM相关MYL3变异(NM_000258.2:c.170C>A, NP_000249.1:p.Ala57Asp),ClinVar报告为「可能致病」。
  • 从该杂合VUS携带者衍生人诱导多能干细胞(iPSCs),用CRISPR/Cas9编辑基因组生成4种同源iPSC系:校正的「健康」对照、纯合VUS MYL3(170C>A)、杂合移码突变MYL3(170C>A/fs)、已知杂合MYL3致病突变(NM_000258.2:c.170C>G)。
  • 对同源iPSC衍生心肌细胞(iPSC-CMs)进行基因表达、肌节结构、细胞大小、收缩力、动作电位和钙处理等检测。

主要发现

  • 杂合VUS MYL3(170C>A)-iPSC-CMs在基因表达、形态或功能水平未显示HCM表型。
  • 基因组编辑的纯合VUS MYL3(170C>A)-和移码突变MYL3(170C>A/fs)-iPSC-CMs系也无症状,支持该特定MYL3变异为良性评估。
  • 携带已知致病MYL3突变(MYL3(170C>G))的基因组编辑同源系和携带MYBPC3(961G>A) HCM变异的携带者特异性iPSC-CMs系进一步评估显示,该联合平台能提供致病性和良性评估。

临床怎么用

  • 该平台可用于评估HCM相关VUS及一般VUS的致病性,辅助临床风险分层。
  • 对无症状「健康」个体中发现的VUS,可采用CRISPR/Cas9编辑iPSCs进行功能验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The progression toward low-cost and rapid next-generation sequencing has uncovered a multitude of variants of uncertain significance (VUS) in both patients and asymptomatic "healthy" individuals. A VUS is a rare or novel variant for which disease pathogenicity has not been conclusively demonstrated or excluded, and thus cannot be definitively annotated. VUS, therefore, pose critical clinical interpretation and risk-assessment challenges, and new methods are urgently needed to better characterize their pathogenicity. METHODS: To address this challenge and showcase the uncertainty surrounding genomic variant interpretation, we recruited a "healthy" asymptomatic individual, lacking cardiac-disease clinical history, carrying a hypertrophic cardiomyopathy (HCM)-associated genetic variant (NM_000258.2:c.170C>A, NP_000249.1:p.Ala57Asp) in the sarcomeric gene MYL3, reported by the ClinVar database to be "likely pathogenic." Human-induced pluripotent stem cells (iPSCs) were derived from the heterozygous VUS MYL3(170C>A) carrier, and their genome was edited using CRISPR/Cas9 to generate 4 isogenic iPSC lines: (1) corrected "healthy" control; (2) homozygous VUS MYL3(170C>A); (3) heterozygous frameshift mutation MYL3(170C>A/fs); and (4) known heterozygous MYL3 pathogenic mutation (NM_000258.2:c.170C>G), at the same nucleotide position as VUS MYL3(170C>A), lines. Extensive assays including measurements of gene expression, sarcomere structure, cell size, contractility, action potentials, and calcium handling were performed on the isogenic iPSC-derived cardiomyocytes (iPSC-CMs). RESULTS: The heterozygous VUS MYL3(170C>A)-iPSC-CMs did not show an HCM phenotype at the gene expression, morphology, or functional levels. Furthermore, genome-edited homozygous VUS MYL3(170C>A)- and frameshift mutation MYL3(170C>A/fs)-iPSC-CMs lines were also asymptomatic, supporting a benign assessment for this particular MYL3 variant. Further assessment of the pathogenic nature of a genome-edited isogenic line carrying a known pathogenic MYL3 mutation, MYL3(170C>G), and a carrier-specific iPSC-CMs line, carrying a MYBPC3(961G>A) HCM variant, demonstrated the ability of this combined platform to provide both pathogenic and benign assessments. CONCLUSIONS: Our study illustrates the ability of clustered regularly interspaced short palindromic repeats/Cas9 genome-editing of carrier-specific iPSCs to elucidate both benign and pathogenic HCM functional phenotypes in a carrier-specific manner in a dish. As such, this platform represents a promising VUS risk-assessment tool that can be used for assessing HCM-associated VUS specifically, and VUS in general, and thus significantly contribute to the arsenal of precision medicine tools available in this emerging field.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Ma N, Zhang JZ, Itzhaki I, et al. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells. Circulation. 2018. PMID: 29914921. doi:10.1161/CIRCULATIONAHA.117.032273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。